Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

BACKGROUND: Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and tolerability in patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Selection of novel drug therapies for patients with relapsed/refractory aggressive lymphoma re...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Francine, Coiffier, Bertrand, Horwitz, Steven, Pro, Barbara, Prince, H Miles, Sokol, Lubomir, Greenwood, Matthew, Lerner, Adam, Caballero, Dolores, Baran, Eugeniusz, Kim, Ellen, Nichols, Jean, Balser, Barbara, Wolfson, Julie, Whittaker, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181623/
https://www.ncbi.nlm.nih.gov/pubmed/25279222
http://dx.doi.org/10.1186/2050-7771-2-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181623/
https://www.ncbi.nlm.nih.gov/pubmed/25279222
http://dx.doi.org/10.1186/2050-7771-2-16

Ejemplares similares